Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 75
- Registration Number
- NCT00025103
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧Southampton General Hospital, Southampton, England, United Kingdom
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Target Recruit Count
- 400
- Registration Number
- NCT00005583
- Locations
- 🇬🇧
Centre for Cancer Research and Cell Biology at Belfast City Hospital, Belfast, Northern Ireland, United Kingdom
🇬🇧Western Infirmary, Glasgow, Scotland, United Kingdom
🇮🇹Azienda Ospedaliera Di Parma, Parma, Italy
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 397
- Registration Number
- NCT00004031
- Locations
- 🇨🇦
Moncton Hospital, Moncton, New Brunswick, Canada
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇨🇦Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT00023855
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3871
- Registration Number
- NCT00041119
- Locations
- 🇺🇸
UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸Dubs Cancer Center at Rogue Valley Medical Center, Medford, Oregon, United States
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-08-02
- Target Recruit Count
- 285
- Registration Number
- NCT00028756
Combination Chemotherapy in Treating Children With Neuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 573
- Registration Number
- NCT00003093
- Locations
- 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸MBCCOP - Hawaii, Honolulu, Hawaii, United States
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1148
- Registration Number
- NCT00002757
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇬🇧Children's Hospital - Sheffield, Sheffield, England, United Kingdom
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3436
- Registration Number
- NCT00005970
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Vermont and State Agricultural College, Burlington, Vermont, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
- Conditions
- Interventions
- Biological: dactinomycinBiological: sargramostimDrug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: etoposideDrug: mercaptopurineDrug: prednisoneDrug: mitoxantrone hydrochlorideDrug: pegaspargaseDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT00002766
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.